Two of the most recently introduced anti-hyperglycaemic drug classes, SGLT2-inhibitors (SGLT2i) and GLP1-receptor agonists (GLP1-RA), have been shown in randomized clinical trials not only to reduce glycaemia1 but also to lower the risk of renal and cardiovascular disease (CVD) outcomes among high-risk individuals with type 2 diabetes (T2D)2–5. Here, GLP1R is linked to cardiovascular disorder.